A Phase II Trial of Bryostatin 1 in Ovarian Cancer Administered by Weekly 24 Hour Intravenous Infusion
OBJECTIVES:
- Evaluate the antitumor activity and toxicity of bryostatin 1 in patients with platinum
resistant ovarian epithelial cancer.
- Determine the response rate in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive bryostatin 1 IV over 24 hours. Treatment repeats weekly for 8 courses in
the absence of disease progression or unacceptable toxicity. Patients achieving stable or
regressive disease may receive additional treatment.
Patients are followed for at least 4 weeks after treatment, then every 3 months.
PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Gordon Jayson, MD
Study Chair
Christie Hospital NHS Foundation Trust
United States: Federal Government
CRC-PHASE-II-PH2/039
NCT00004008
July 1999
May 2003
Name | Location |
---|